体内分布
分子成像
药理学
药代动力学
体内
口服
化学
吸收(声学)
临床前影像学
全身给药
癌症
给药途径
医学
药物输送
生物利用度
多糖
广告
体外
拉顿
药品
癌症研究
组织分布
毒品携带者
作者
Fábio Fernando Alves da Silva,Sofia Nascimento dos Santos,Lucas de Freitas Pedrosa,Vinicius Gonçalves Rodrigues,Jonathas Xavier Pereira,Jhonatas Pedrosa Marim Pereira,Dino Seigo Gushiken,Thiécla Katiane Osvaldt Rosales,Luís Alberto Pereira Dias,Patrick Jack Spencer,João Paulo Fabi,Emerson Soares Bernardes
出处
期刊:Biomacromolecules
[American Chemical Society]
日期:2026-03-24
卷期号:27 (4): 2449-2465
被引量:4
标识
DOI:10.1021/acs.biomac.5c00915
摘要
High Resolution Image Download MS PowerPoint Slide This study employed molecular imaging to evaluate MCP (PectaSol-C, modified citrus pectin, a complex polysaccharide with antitumor potential) absorption and pharmacokinetics following oral and intravenous (IV) administration. MCP was radiolabeled with technetium-99m ( 99m Tc) ([ 99m Tc]MCP), allowing precise in vivo tracking. Imaging and biodistribution analyzes revealed low tumor uptake of IV [ 99m Tc]MCP, with predominant renal and hepatobiliary clearance. Within tumors, MCP was detected at low levels and did not bind to viable cells. Consistent with these findings, IV administration produced only modest antitumor effects (∼50% tumor growth reduction) in SKOV-3 (ovarian), MKN45 (gastric), and 4T1 (breast) grafts, whereas oral administration was ineffective due to extremely poor absorption (bioavailability <0.01%). Notably, faster clearance of [ 99m Tc]MCP in galectin-3 (Gal-3) knockout mice suggests a role for Gal-3 in systemic retention or an indirect contribution to antitumor activity. These findings provide new insights into MCP pharmacological profile, highlight the limitations of oral delivery, and underscore the need for improved delivery strategies to enhance the therapeutic potential of pectin-based cancer treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI